Prediction of differences in in vivo oral clearance of N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethylamine monohydrochloride (NE-100) between extensive and poor metabolizers from in vitro metabolic data in human liver microsomes lacking CYP2D6 activity and recombinant CYPs

Reference

• BISCHOFF, K. B., DEDRICK, R. L., ZAHARKO, D. S. and LONGSTRETH, J. A., 1971, Mothotrexate pharmacokinetics. Journal of Pharmaceutical Sciences, 60, 1128–1133.
   PubMed Web of Science ®Google Scholar
• BOXENBAUM, H., 1980, Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance extrapolation of data to benzodiazepines and phenytoin. Journal of Pharmacokinetics and Biopharmaceutics, 8, 165–176.
   PubMedGoogle Scholar
• BOXENBAUM, H., 1982, Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics, 10, 201–227.
   PubMedGoogle Scholar
• BROLY, F., GAEDIGK, A., HEIM, M., EICHELBAUM, M., MORIKE, K. and MEYER, U. A., 1991, Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA and Cell Biology, 10, 545–558.
   PubMed Web of Science ®Google Scholar
• CRESPI, C. L., 1995, Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Advances in Drug Research, 26, 179–235.
   Google Scholar
• DEDRICK, R. L., FORESTER, D. D., CANNON, J. N., EL DAREEN, S. M. and MELLETT, L. B., 1973, Pharmacokinetics of 1-13-D-arabinofuranosylcytosine (Ara-C) deaminonation in several species. Biochemical Pharmacology, 22, 2405–2417.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., 1995, Human cytochrome P450 enzymes. In P. R. Ortiz-de Montellano (ed.), Cytochrome P450 (New York: Plenum), pp. 473–535.
   Google Scholar
• HIGASHIKAWA, F., MURAKAMI, T., KANEDA, T. and TAKANO, M., 1999, In-vivo and in-vitro metabolic clearance of midazolam, a cytochrome P450 3A substrate, by the liver under normal and increased enzyme activity in rats. Journal of Pharmacy and Pharmacology, 27, 405–410.
   Google Scholar
• HORAI, Y., NAKANO, M., ISHIZAKI, T., ISHIKAWA, K., ZHOU, H. H., ZHOU, B. I., LIAO, C. L. and ZHANG, L. M., 1989, Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clinical Pharmacology and Therapeutics, 46, 198–207.
   PubMed Web of Science ®Google Scholar
• HOUSTON, J. B., 1994, Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochemical Pharmacology, 47, 1469–1479.
   PubMed Web of Science ®Google Scholar
• HOUSTON, J. B. and CAELILE, D. J., 1997, Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metabolism Reviews, 29, 891–922.
   PubMed Web of Science ®Google Scholar
• IWATSUBO, T., HIROTA, N., 00IE, T., SUZUKI, H. and SUGIYAMA, Y., 1996, Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharmaceutics and Drug Disposition, 17, 273–310.
   Google Scholar
• IWATSUBO, T., HIROTA, N., 00IE, T., SUZUKI, H., SHIMADA, N., CHIBA, K., ISHIZAKI, T., GREEN, C. E., TYSON, C. A. and SUGIYAMA, Y., 1997a, Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacology and Therapeutics, 73, 147–171.
   Google Scholar
• IWATSUBO, T., SUZUKI, H., SHIMADA, N., CHIBA, K., ISHIZAKI, T., GREEN, C. E., TYSON, C. A., YOKOI, T., KAMATAKI, T. and SUGIYAMA, Y., 1997b, Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes. Journal of Pharmacology and Experimental Therapeutics, 282, 909–919.
   PubMed Web of Science ®Google Scholar
• LAVE, T., DUPIN, S., SCHMITT, C., VALLES, B., UBEAUD, G., CHOU, R. C., JAECH, D. and COASSOLO, P. H., 1997, The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharmaceutical Research, 14, 152–155.
   PubMed Web of Science ®Google Scholar
• LENNARD, M. S., TUCKER, G. T., SILAS, J. H. and WOODS, H. F., 1986, Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol. Xenobiotica, 16, 435–447.
   PubMed Web of Science ®Google Scholar
• LESSARD, E., YESSINE, M. A., HAMELIN, B. A., O'HARA, G., LEBLANC, J. and TURGEON, J., 1999, Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics, 9, 435–443.
   Google Scholar
• LIN, J. H., 1995, Species similarities and differences in pharmacokinetics. Drug Metabolism and Disposition, 23, 1008–1021.
   PubMed Web of Science ®Google Scholar
• LLERENA, A., ALM, C., DAHL, M. L., EKQVIST, B. and BERTILSSON, L., 1992, Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Therapeutic Drug Monitoring, 14, 92-97. MURRAY, M., 1992, P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease. Clinical Pharmcokinetics, 23, 132–146.
   Google Scholar
• NAKAJIMA, M., NAKAMURA, S., TOKUDOME, S., SHIMADA, N., YAMAZAKI, H. and YOKOI, T., 1999, Azelastine N-demetylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metabolism and Disposition, 27, 1381–1391.
   PubMed Web of Science ®Google Scholar
• OBACH, R. S., 1996, The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations. Drug Metabolism and Disposition, 24, 1047–1049.
   PubMed Web of Science ®Google Scholar
• OKUYAMA, S., IMAGAWA, Y., OGAWA, S., ARAKI, H., AJIMA, A., TANAKA, M., MURAMATSU, M., NAKAZATO, A., YAMAGUCHI, K., YOSHIDA, S. and OTOMO, S., 1993, NE-100, a novel sigma receptor ligand: in vivo tests. Life Science, 53, 285–290.
   Web of Science ®Google Scholar
• PANE, A., WILKINSON, G. R. and SHAND, D. G., 1977, Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. Journal of Pharmacology and Experimental Therapeutics, 200, 420–424.
   PubMed Web of Science ®Google Scholar
• ROBERTS, M. S. and ROWLAND, M., 1986a, A dispersion model of hepatic elimination: 1. Formation of the model and bolus considerations. Journal of Pharmacokinetics and Biopharmaceutics, 14, 227–260.
   PubMedGoogle Scholar
• ROBERTS, M. S. and ROWLAND, M., 1986b, Correlation between in vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model. Journal of Pharmacy and Pharmacology, 38, 177–181.
   PubMed Web of Science ®Google Scholar
• SAUER, J. M., PONSLER, G. D., MATTIUZ, E. L., LONG, A. J., WIRCHER, J. W., THOMASSON, H. R. and DESANTE, K. A., 2003, Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metabolism and Disposition, 31, 98–107.
   PubMed Web of Science ®Google Scholar
• SAWADA, Y, HANANO, M., SUGIYAMA, Y. and IGA, T., 1984, Prediction of the disposition of 13-lactam antibiotics in human from pharmacokinetic parameters in animals. Journal of Pharmacokinetics and Biopharnzaceutics, 12, 241–261.
   PubMed Web of Science ®Google Scholar
• SUGIYAMA, Y., SAWADA, Y., IGA, T. and HANANO, M., 1988, Xenobiotic metabolism and disposition. In R. Kato, R. W. Estabrook and M. N. Cayan (eds), Proceedings of the 2nd International ISSX Meeting (London: Taylor & Francis), pp. 225–235.
   Google Scholar
• WAGNER, F., KALUSCHE, D., TRENK, D., JAHNCHEN, E. and ROSKAMM, H., 1987, Drug interaction between propafenone and metoprolol. British Journal of Clinical Pharmacology, 24, 213–220.
   PubMed Web of Science ®Google Scholar
• WILKINSON, G. R., 1987, Clearance approaches in pharmacology. Pharmacological Reviews, 39, 1–47.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO, T., HAGIMA, N., NAKAMURA, M., KOHNO, Y., NAGATA, K. and YAMAZOE, Y., 2003a, Differences in cytochrome P450 forms involved in the metabolism of N,N-dipropy1-2-[4-methoxy-3 -(2-phenylethoxy)phenyThethyl-amine-mono hydro-chloride (NE-100), a novel sigma ligand, in human liver and intestine. Drug Metabolism and Disposition, 31, 60–66.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO, T., HAGIMA, N., FUKASAWA, M., YAMAGUCHI, J., NAKAMURA, M., KOHNO, Y., NAGATA, K. and YAMAZOE, Y., 2003b, Metabolism of N,N-dipropy1-2-[4-methoxy-3-(2-phenylethoxy) phenyl]-ethyl-amine-mono hydrochloride (NE-100), a novel sigma ligand: contribution of cytochrome P450 forms involved in the formation of individual metabolites in human liver and small intestine. Drug Metabolism and Pharmacokinetics, 18, 173–185.
   PubMedGoogle Scholar